Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Biomarker Analysis of the IMmotion010 Study
2024 ASCO Annual Meeting
Laurence Albiges, MD, PhD, of Gustave Roussy, Université Paris-Saclay, discusses phase III findings showing that high baseline serum KIM-1 levels were associated with poorer prognosis but improved clinical outcomes with atezolizumab vs placebo in patients with renal cell carcinoma at increased risk of recurrence after resection. Increased post-treatment KIM-1 levels were found to be associated with worse disease-free survival (Abstract 4506).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Currently, standard of care in the adjuvant setting is pembrolizumab for patients that have had surgery and that are considered at high risk of recurrence for RCC. What we don't know is how we can better select our patients. At this recent ASCO, I had the chance to present an exploratory analysis within the IMmotion 010 study. This trial tested atezolizumab in the adjuvant setting did not demonstrate the disease-free survival benefit. But here the question is, can we do a better job with defining circulating biomarker? And so the work conducted, which is translational exploratory analysis, was a two-step process, the first one being identifying circulating proteins that were associated with an increase at time of disease recurrence. And when screening over 3000 proteins, one stands out, KIM-1, which stands for kidney injury molecule one, which clearly had an increase at the time of disease recurrence.
Then we took on to the next step, which was to assess the association of high baseline KIM-1, meaning after surgery with disease-free survival. And we confirmed that KIM-1 is a prognostic circulating biomarker that was actually already demonstrated in the past in other adjuvant studies, but it is the first time that not only we saw a prognostic value, but also a potentially predictive value. Indeed, in our data sets, not only patients with high KIM-1 had a worst disease-free survival, but atezolizumab was associated with an increased benefit with regard to disease-free survival over placebo in those patients with high baseline KIM-1. Furthermore, we showed that the kinetic of this circulating biomarker is important because any increase in this biomarker was associated with worse DFS.
Ultimately, we further validate the fact that patients at time of disease recurrence had a significant increase in KIM-1 using a different assay than the screening one. So taken all together, what these data are showing us is that circulating KIM-1 is a potential biomarker for prognostic assessment in the adjuvant space, but also potentially for the predictive use of checkpoint inhibitor in the adjuvant setting. And that actually come as a confirmation of prior work recently presented within the CheckMate 914 study as well. Of course, it will require further prospective validation, but this biomarker could help us in the setting of the adjuvant space to define a go/no-go strategy and potentially as well for monitoring patients and detect earlier recurrence. It is the first potential minimal residual disease biomarker that is being discussed in RCC.
Related Videos
The ASCO Post Staff
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and The University of Sydney, discusses final results with up to 10 years’ follow-up data of the COMBI-AD study of patients with stage III BRAF-mutated melanoma who received adjuvant dabrafenib plus trametinib (Abstract 9500).
The ASCO Post Staff
Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, and Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, discuss two key studies on B-cell maturation antigen (BCMA)-directed therapies: CARTITUDE-4 on ciltacabtagene autoleucel in patients with functional high-risk multiple myeloma; and DREAMM-7 on belantamab mafodotin-blmf plus bortezomib and dexamethasone vs daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory disease.
The ASCO Post Staff
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses up to 5.5 years of follow-up data from the phase II CAPTIVATE study, showing that in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), fixed duration ibrutinib plus venetoclax continues to provide clinically meaningful progression-free disease in those with high-risk genomic features as well as in the overall population (Abstract 7009).
The ASCO Post Staff
Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).
The ASCO Post Staff
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).